Vitamin D deficiency has been observed in autoimmune rheumatic diseases, such as rheumatoid arthritis. The aim was to study vitamin D in patients with systemic lupus erythematosus (SLE) and its relationship with disease activity.
Methods
In a cohort of 45 patients with SLE, 41 females and 4 males, aged 47.07 ± 2.17 years (mean ± SEM), and range = 21–79 years, 25(OH)D3 levels were determined by electrochemiluminescence. C3 and C4 levels were also analyzed. SLE disease activity was estimated by SLEDAI-2K. Observations were also performed in a control group matched for age and sex.
Results
In this cohort of SLE patients, 25(OH)D3 levels were 40.36 ± 2.41 nmol/L (mean ± SEM) as opposed to 60.98 ± 4.28 nmol/L in the control group (p < 0.001, Student’s t test). Vitamin D levels were related to C3 (p < 0.001, linear regression analysis), correlation coefficient 0.106, r2 = 0.011, and C4 (p < 0.001); correlation coefficient 0.316 and r2 = 0.100; and inversely related to disease activity (p < 0.001), correlation coefficient −0.572 and r2 = 0.327. 25(OH)D3 levels were 17.73 ± 1.20 nmol/L and 12.24 ± 0.93 nmol/L, in the groups without and with renal involvement, respectively (p = 0.001, Student’s t test).
Conclusions
Vitamin D levels are low in SLE patients and are inversely related to disease activity. Routine screening for vitamin D levels should be performed in SLE patients.
BouillonRMarcocciCCarmelietG, et al.Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev2019; 40: 1109–1151.
2.
ChristakosSDhawanPVerstuyfA, et al.Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev2016; 96: 365–408.
3.
CharoenngamNShirvaniAHolickMF. Vitamin D for skeletal and non-skeletal health: What we should know. J Clin Orthopaed Trauma2019; 10: 1082–1093.
4.
WackerMHolickMF. Sunlight and vitamin D. Dermatoendocrinol2013; 5: 51–108.
5.
BikleDD. Extraskeletal actions of vitamin D. Ann N Y Acad Sci2016; 1376: 29–52.
6.
DelucaHFCantornaMT. Vitamin D: its role and uses in immunology1. Faseb J2001; 15: 2579–2585.
7.
HaasJ. [Vigantol--Adolf Windaus and the history of vitamin D]. Wurzbg Medizinhist Mitt2007; 26: 144–181.
8.
VeldmanCMCantornaMTDeLucaHF. Expression of 1,25-Dihydroxyvitamin D3 Receptor in the Immune System. Arch Biochem Biophys2000; 374: 334–338.
9.
LiuPTStengerSLiH, et al.Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science2006; 311: 1770–1773.
10.
BadenhoopKKahlesHPenna-MartinezM. Vitamin D, immune tolerance, and prevention of type 1 diabetes. Curr Diab Rep2012; 12: 635–642.
11.
CyprianFLefkouEVaroudiK, et al.Immunomodulatory effects of vitamin D in pregnancy and beyond. Front Immunol2019; 10: 2739.
12.
AdoriniLPennaG. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol2009; 188: 251–273.
13.
Illescas-MontesR.Melguizo-RodríguezLRuizC, et al.Vitamin D and autoimmune diseases. Life Sci2019; 233: 116744.
14.
CzajaAJMontano-LozaAJ. Evolving role of vitamin D in immune-mediated disease and its implications in autoimmune hepatitis. Dig Dis Sci2019; 64: 324–344.
15.
SongGGBaeSCLeeYH. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol2012; 31: 1733–1739.
16.
CutoloMOtsaKUprusM, et al.Vitamin D in rheumatoid arthritis. Autoimmun Rev2007; 7: 59–64.
17.
Kostoglou-AthanassiouIAthanassiouPLyrakiA, et al.Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab2012; 3: 181–187.
18.
HongQXuJXuS, et al.Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology2014; 53: 1994–2001.
19.
VanAmerongenBMDijkstraCDLipsP, et al.Multiple sclerosis and vitamin D: an update. Eur J Clin Nutr2004; 58: 1095–1109.
20.
KragtJvan AmerongenBKillesteinJ, et al.Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler J2009; 15(1): 9–15.
21.
CantornaMTHayesCEDeLucaHF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci1996; 93: 7861–7864.
22.
Pierrot-DeseillignyCSouberbielleJC. Widespread vitamin D insufficiency: a new challenge for primary prevention, with particular reference to multiple sclerosis. La Presse Médicale2011; 40: 349–356.
23.
MarkBLCarsonJAS. Vitamin D and autoimmune disease-implications for practice from the multiple sclerosis literature. J Am Diet Assoc2006; 106: 418–424.
24.
LittorinBBlomPSchölinA, et al.Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia2006; 49: 2847–2852.
25.
GreerRMPortelliSLHungBSM, et al.Serum vitamin D levels are lower in Australian children and adolescents with type 1 diabetes than in children without diabetes. Pediatr Diabetes2013; 14: 31–41.
26.
ZipitisCSAkobengAK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child2008; 93: 512–517.
27.
YellJWojnarowskaF. Diagnosis and management of systemic lupus erythematosus. Sun protection is vital. BMJ1993; 307(6909): 939.
28.
Aharon-MaorAShoenfeldY. [The role of ultraviolet light, and sun and fluorescent light, in the pathogenesis of systemic lupus erythematosus]. Harefuah1998; 135: 295–299.
29.
GuanSYCaiHYWangP, et al.Association between circulating 25‐hydroxyvitamin D and systemic lupus erythematosus: a systematic review and meta‐analysis. Int J Rheum Dis2019; 22: 1803–1813.
30.
AmitalHSzekaneczZSzücsG, et al.Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?: Table 1. Ann Rheum Dis2010; 69: 1155–1157.
31.
WatadANeumannSGSorianoA, et al.Vitamin D and Systemic Lupus Erythematosus: Myth or Reality?Isr Med Assoc J2016; 18: 177–182.
32.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis2019; 78: 1151–1159.
Romero-DiazJIsenbergDRamsey-GoldmanR. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Research2011; 63(Suppl 11): S37–S46.
35.
ShahinDEl-FarahatyRMHoussenME, et al.Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17. Lupus2017; 26: 917–926.
36.
MokCCBirminghamDJLeungHW, et al.Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology2012; 51: 644–652.
37.
YaoHHTangSMWangZM, et al.[Study of bone mineral density and serum bone turnover markers in newly diagnosed systemic lupus erythematosus patients]. Beijing da Xue Xue Bao Yi Xue Ban2018; 50: 998–1003.
38.
KamenDLCooperGSBoualiH, et al.Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev2006; 5: 114–117.
39.
BogaczewiczJSysa-JedrzejowskaAArkuszewskaC, et al.Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters. Lupus2012; 21: 477–484.
40.
BaeSCLeeYH. Association between Vitamin D level and/or deficiency, and systemic lupus erythematosus: a meta-analysis. Cell Mol Biol2018; 64: 7–13.
41.
IslamMAKhandkerSSAlamSS, et al.Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Autoimmun Rev2019; 18: 102392.
42.
SarkarMKHileGATsoiLC, et al.Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis2018; 77: 1653–1664.
43.
AhluwaliaJMarschA. Photosensitivity and photoprotection in patients with lupus erythematosus. Lupus2019; 28: 697–702.
44.
KleinRGArnaudSBGallagherJC, et al.Intestinal calcium absorption in exogenous hypercortisonism. J Clin Invest1977; 60: 253–259.
45.
O'LearyTJJonesGYipA, et al.The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. New Engl J Med1986; 315: 727–730.
46.
JulkunenHEkblom-KullbergSMiettinenA. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol Int2012; 32: 2445–2451.
47.
AbediazarSJafari-NakhjavaniMGhorbanihaghjoA, et al.Serum levels of CXCL10 and vitamin D in patients with lupus nephritis. Iran J Kidney Dis2019; 13: 389–397.
48.
SunJZhangSLiuJS, et al.Expression of vitamin D receptor in renal tissue of lupus nephritis and its association with renal injury activity. Lupus2019; 28: 290–294.
49.
JinJYeMZhaoL, et al.The novel involvement of podocyte autophagic activity in the pathogenesis of lupus nephritis. Histol Histopathol2018; 33: 803–814.
50.
YuQQiaoYLiuD, et al.Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy. Arthritis Res Ther2019; 21: 19.
